Prescrire's ratings of new drugs in 2021: A brief review
Prescrire International
; 31(236):100-102, 2022.
Article
in English
| EMBASE | ID: covidwho-1912842
ABSTRACT
Three new drugs, all based on messenger RNA or small interfering RNA technology, represented a major therapeutic advance in 2021. But the bigger picture is that most of the new authorisations that advanced patient care were adaptations of existing drugs. And that more than half of this year's new authorisations were not advances, and in fact about one-tenth represented a step backwards compared to existing options.
ad 26cov 2s vaccine; ad26.cov2.s vaccine; amphetamine; apalutamide; apomorphine; atezolizumab; avapritinib; avelumab; belantamab mafodotin; benfluorex; bevacizumab; botulinum toxin; botulinum toxin A; brentuximab vedotin; brexucabtagene autoleucel; brimonidine; budesonide; bulevirtide; burosumab; cabotegravir; cefiderocol; chadox 1s; cyclosporine; dapagliflozin; docetaxel; eculizumab; elasomeran; elexacaftor plus ivacaftor plus tezacaftor; encorafenib; enoxaparin; erenumab; etravirine; fenfluramine; Flt3 ligand; gilteritinib; givosiran; glucagon; human growth hormone; isatuximab; janssen covid 19vaccine; larotrectinib; ledipasvir plus sofosbuvir; lidocaine; lumasiran; naloxone; new drug; nintedanib; olaparib; omalizumab; onasemnogene abeparvovec; plerixafor; rilpivirine; rituximab; sevelamer; sevelamer carbonate; siponimod; sofosbuvir; sofosbuvir plus velpatasvir; solriamfetol; tozinameran; vaxzevria; acute myeloid leukemia; adverse event; anaplastic large cell lymphoma; cardiovascular risk; chronic hepatitis C; chronic hepatitis D; clinical evaluation; coronavirus disease 2019; cystic fibrosis; dispersible tablet; drug efficacy; drug industry; drug shortage; eosinophilic esophagitis; excessive daytime sleepiness; gastrointestinal stromal tumor; gene mutation; glaucoma; Gram negative infection; heart failure; hepatic porphyria; hepatitis C; human; Human immunodeficiency virus infection; hyperphosphatemia; hypoglycemia; liver cell carcinoma; malignant neoplasm; mantle cell lymphoma; marketing authorization; medical literature; metastatic castration sensitive prostate cancer; metastatic colorectal cancer; migraine; multiple myeloma; myelooptic neuropathy; nonhodgkin lymphoma; Noonan syndrome; opiate overdose; ovary cancer; oxalosis 1; pandemic; Parkinson disease; patient care; pemphigus vulgaris; polyarthritis; product recall; review; risk benefit analysis; severe myoclonic epilepsy in infancy; small cell lung cancer; spinal muscular atrophy; transitional cell carcinoma; urine incontinence; vernal conjunctivitis; X linked hypophosphatemic rickets; adcetris; aimovig; ayvakyt; baqsimi; bavencio; blenrep; braftovi; comirnaty; crysvita; epclusa; erleada; fetcroja; fintepla; forxiga; givlaari; harvoni; hepcludex; intelence; jorveza; kaftrio; lynparza; mabthera; mayzent; mozobil; nyxoid; ofev; oxlumo; rekambys; renvela; sarclisa; soliris; sovaldi; spikevax; sunosi; taxotere; tecartus; tecentriq; verkazia; vitrakvi; vocabria; xolair; xospata; zolgensma
Search on Google
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Prescrire International
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS